$Lumos Pharma(LUMO.US)$ Lumos Pharma to Host Virtual Key Opinion Leader Webinar to Discuss Phase 2 OraGrowtH Trial Data and Treatment Potential of Oral LUM-201 for Pediatric Growth Hormone Deficiency
$Lumos Pharma(LUMO.US)$The company reported quarterly sales of $7.00 thousand which missed the analyst consensus estimate of $320.00 thousand by 97.81 percent. This is a 98.59 percent decrease over sales of $497.00 thousand the same period last year.
$Lumos Pharma(LUMO.US)$Lumos Pharma Announces Topline Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201 in PGHD Met All Primary and Secondary Endpoints Phase 2 Data Provide Supportive Evidence to Advance Oral LUM-201 to Phase 3 •OraGrowtH210 Results Show LUM-201 Dose of 1.6 mg/kg Achieves Annualized Height Velocities (AHV) of 8.2 cm/yr at 6 Months and 8.0 cm/yr at 12 Months, Comparable to Growth Rates for Moderate PGHD Population •Delta at 6 and 12-month AHV Between Optima...
Lumos Pharma股票討論區
News
Update
Seminar Started
Lumos Pharma to Host Virtual Key Opinion Leader Webinar to Discuss Phase 2 OraGrowtH Trial Data and Treatment Potential of Oral LUM-201 for Pediatric Growth Hormone Deficiency
Hehehe
News!
Met All Primary and Secondary Endpoints
Phase 2 Data Provide Supportive Evidence to Advance Oral LUM-201 to Phase 3
•OraGrowtH210 Results Show LUM-201 Dose of 1.6 mg/kg Achieves Annualized Height Velocities (AHV) of 8.2 cm/yr at 6 Months and 8.0 cm/yr at 12 Months, Comparable to Growth Rates for Moderate PGHD Population
•Delta at 6 and 12-month AHV Between Optima...
暫無評論